PTGES3

Across TCGA pan-cancer cohorts, PTGES3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTGES3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PTGES3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTGES3 expression acts as an unfavorable survival marker.

STAD, COAD, and ESCA are the cancer types where PTGES3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
COAD	DFS	Median	All	0.073	0.781	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	0.078	0.489	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTGES3–STAD (OS)

Open the STAD breakdown →